We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Esperion Therapeutics Inc | NASDAQ:ESPR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.09 | -4.52% | 1.90 | 1.84 | 3.50 | 2.01 | 1.88 | 2.01 | 4,198,930 | 05:00:10 |
| | |
Per Share and
Accompanying Common Stock Warrant |
| |
Per Pre-Funded
Warrant and Accompanying Common Stock Warrant |
| |
Total
|
| |||||||||
Offering Price
|
| | | $ | 1.675 | | | | | $ | 1.674 | | | | | $ | 55,540,035.48 | | |
Placement Agent’s Fees(1)
|
| | | $ | 0.117 | | | | | $ | 0.117 | | | | | $ | 3,889,270.09 | | |
Proceeds to us, before expenses(2)
|
| | | $ | 1.558 | | | | | $ | 1.557 | | | | | $ | 51,650,765.39 | | |
| | |
Page
|
| |||
| | | | S-1 | | | |
| | | | S-2 | | | |
| | | | S-4 | | | |
| | | | S-6 | | | |
| | | | S-11 | | | |
| | | | S-13 | | | |
| | | | S-14 | | | |
| | | | S-16 | | | |
| | | | S-19 | | | |
| | | | S-21 | | | |
| | | | S-21 | | | |
| | | | S-21 | | | |
| | | | S-22 | | |
| | | | | | Page | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 24 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | |
|
Offering price per share
|
| | | | | | | | | $ | 1.675 | | |
|
Historical net tangible book value per share as of December 31, 2022
|
| | | $ | (4.23) | | | | | | | | |
|
Increase in net tangible book value per share attributable to this offering
|
| | | $ | 1.75 | | | | | | | | |
|
As adjusted net tangible book value per share after giving effect to this offering
|
| | | | | | | | | $ | (2.48) | | |
|
Dilution in net tangible book value per share to investors participating in this offering
|
| | | | | | | | | $ | 4.16 | | |
| | | | | | Page | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 24 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | | |
| | | | | 27 | | |
1 Year Esperion Therapeutics Chart |
1 Month Esperion Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions